Accéder au contenu
Merck

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Oncotarget (2017-12-07)
Mateusz Opyrchal, Malgorzata Gil, Jeffrey L Salisbury, Mathew P Goetz, Vera Suman, Amy Degnim, James McCubrey, Tufia Haddad, Ianko Iankov, Chenye B Kurokawa, Nicole Shumacher, James N Ingle, Evanthia Galanis, Antonino B D'Assoro
RÉSUMÉ

Although the majority of breast cancers initially respond to the cytotoxic effects of chemotherapeutic agents, most breast cancer patients experience tumor relapse and ultimately die because of drug resistance. Breast cancer cells undergoing epithelial to mesenchymal transition (EMT) acquire a CD44

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human SMAD5